First author | Type of HT | Dose of HT | Route of HT | Duration of HTa-mean (range/SD)b |
---|---|---|---|---|
Challberg [33] | ET, EPT and tibolone | NS | NS | 3.4 (0.1-19) |
Chapman [37] | NS | NS | NS | 6 (0.75-9) |
Eisen [21] | ET and EPT | NS | NS | 3.85c (NS) |
Finch [38] | ET and EPT | NS | NS | NS |
Gabriel [28] | ET and EPT | NS | NS | 2.79 ± 3.22 |
Garcia [30] | NS | NS | Systemic HT (60%) | NS |
Heiniger [29] | NS | NS | NS | NS |
Johansen [36] | ET, EPT and tibolone | NS | Systemic HT (39.28%) & local/vaginal HT (6.54%) | NS |
Kotsopoulos [31] | ET and EPT | NS | NS | 4.35(0.05-25)c |
Madalinska [34] | EPT and tibolone | NS (standard) | Systemic HT (Oral/transdermal) | 3 ± 2.3 |
Michelsen [35] | NS | NS | Systemic (Oral/transdermal) | NS |
Rebbeck [20] | ET and EPT | NS | NS | NS |
Tucker [32] | ET | NS | Systemic HT (20% - oral and transdermal) & local/vaginal HT (8%) | NS |